(Q36916936)

17 August 2017

1 reference

title

Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction (English)

1 reference

17 August 2017

1 reference

1 reference

William Storms

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

13

1 reference

17 August 2017

page(s)

2173-2187

1 reference

The expanding role of leukotriene receptor antagonists in chronic asthma.

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

A review of montelukast in the treatment of asthma and allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Hospitalizations with primary versus secondary discharge diagnoses of asthma: implications for pediatric asthma surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Molecular and functional aspects of human cysteinyl leukotriene receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Cysteinyl leukotriene receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast adult (10-mg film-coated tablet) and pediatric (5-mg chewable tablet) dose selections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast dose selection in children ages 2 to 5 years: comparison of population pharmacokinetics between children and adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast in the treatment of allergic rhinitis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

The efficacy of montelukast in the treatment of cat allergen-induced asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 yr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Comparative effects of long-acting beta2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Time efficacy of a single dose of montelukast on exercise-induced asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

The national montelukast survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Efficacy and safety of montelukast in adults with asthma and allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

The role of leukotrienes in airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

Intermittent Inhaled Corticosteroids in Infants with Episodic Wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.13.2173

10.1517/14656566.8.13.2173

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference